Literature DB >> 27873052

Symptoms of uterine myomas: data of an epidemiological study in Germany.

Dolores Foth1, Friedrich-Wilhelm Röhl2, Cornelia Friedrich3, Heike Tylkoski4, Thomas Rabe5, Thomas Römer6, Ann Kitay2, Hans-Joachim Ahrendt7.   

Abstract

PURPOSE: Currently, no reliable data are available concerning the type and frequency of symptoms in premenopausal women with uterine myomas.
METHODS: 2296 women were examined by means of vaginal ultrasound for the presence of myomas in seven gynaecological outpatient departments in Germany. From this population, 1314 premenopausal women between the ages of 30 and 55 years were evaluated to determine the type and frequency of myoma-related symptoms and their relationship to anamnestic factors, and the number, size, and location of the myomas. Standardised questionnaires were used to record the symptoms.
RESULTS: Prevalence: In almost every second premenopausal woman (n = 639; 48.6%), uterine myomas were diagnosed. The frequency of myomas increased continuously with age and was highest in women between 46 and 50 years (65.2%). Age itself was found to be the main risk factor for the presence of myomas (p < 0.001). SYMPTOMS: 54.3% (n = 347) of the women suffered from myoma-related symptoms. The four main symptoms were identified as: Heavy menstrual bleeding (40.7%), dysmenorrhoea (28.2%), lower abdominal pain (14.9%), and intermenstrual bleeding (14.1%). In the majority of cases, the symptoms occurred simultaneously. Determinants for symptoms: Symptoms did not follow a clear age-related trend, whilst the number and size of the myomas did determine the presence of symptoms. The main influencing factor for the presence of intermenstrual bleeding was the location of the myomas.
CONCLUSIONS: The high prevalence of uterine myomas highlights the importance of the diagnosis uterine myomas in standard gynaecological practice: The presence of only one myoma caused symptoms in 46.5% and small myomas of up to 2 cm in diameter resulted in symptoms in 39.5%.

Entities:  

Keywords:  Heavy menstrual bleeding, dysmenorrhoea, lower abdominal pain; Prevalence of myomas; Uterine myomas

Mesh:

Year:  2016        PMID: 27873052     DOI: 10.1007/s00404-016-4239-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Combined procedure of the transcervical radiofrequency ablation (TRFA) system and surgical hysteroscopy. Increased risk or safe procedure?

Authors:  Elvin Piriyev; Sven Schiermeier; Thomas Römer
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-02-17       Impact factor: 1.627

2.  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

Authors:  Ayman Al-Hendy; Andrea S Lukes; Alfred N Poindexter; Roberta Venturella; Claudio Villarroel; Hilary O D Critchley; Yulan Li; Laura McKain; Juan C Arjona Ferreira; Andria G M Langenberg; Rachel B Wagman; Elizabeth A Stewart
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

3.  Term Delivery in an Infertile Patient after Transcervical Radiofrequency Fibroid Ablation and Assisted Reproductive Technology.

Authors:  Gregor Pschadka; Matthias Engelhardt; Caroline Niehoff; David Toub
Journal:  J Gynecol Surg       Date:  2019-08-01

4.  Comparison of Clinical Symptoms of Assumed vs. Actual Uterine Fibroids - Symptoms Described by Patients and Ultrasound Findings.

Authors:  Nina Isabelle Knudsen; Klaus-D Wernecke; Heribert Kentenich; Matthias David
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-30       Impact factor: 2.915

5.  Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results.

Authors:  Ladina Christoffel; Thomas Römer; Sven Schiermeier
Journal:  Med Devices (Auckl)       Date:  2021-03-03

6.  Epidemiology of uterine fibroid in black African women: a systematic scoping review.

Authors:  Imran O Morhason-Bello; Clement A Adebamowo
Journal:  BMJ Open       Date:  2022-08-03       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.